The U.S. Department of Justice said it is no longer pursuing legal action against Ranbaxy Laboratories after the generic-drug firm submitted documents for an inquiry into alleged production violations at two of its facilities in India. An FDA ban on some of Ranbaxy's products remains in effect despite the department's move.

Related Summaries